|
Intra-Cellular Therapies Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia
|
4
|
771
|
September 12, 2017
|
|
Intra-Cellular Therapies Announces Positive Topline Results from Study 402
|
3
|
342
|
November 29, 2020
|
|
Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
|
0
|
301
|
April 2, 2020
|
|
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
|
0
|
239
|
February 22, 2021
|
|
(Iti-007/lumateperone) Intra-Cellular Therapies stock soars 38% premarket after FDA approves
|
32
|
838
|
December 24, 2019
|